Scutellaria barbata Extract for Estrogenic Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current hormone replacement therapies and selective estrogen receptor modulators (SERMs) for treating menopausal symptoms and breast cancer have undesirable side effects, such as increased risk of breast cancer and uterine cancer, and do not effectively address climacteric symptoms without risking mammary and uterine hyperplasia.
Innovation Solution
A plant extract composition from Scuttelaria barbata D. Don of the Labiatae family, which can be in the form of an aqueous, ethanolic, or purified extract, is used to provide estrogenic effects that treat or prevent climacteric symptoms, osteoporosis, and uterine and breast cancers without increasing the risk of mammary or uterine hyperplasia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If hormone replacement therapy (HRT) with estradiol is used to treat menopausal symptoms and osteoporosis, then climacteric symptoms and bone density are improved, but the risk of breast cancer and uterine cancer increases
Solution Approach 1:
The patent segments the estrogenic effect into two distinct pathways by utilizing two different plant extracts: one providing estrogenic activity for menopausal symptom relief and bone protection, and another providing anti-estrogenic activity to counteract cancer risks. This segmentation allows simultaneous achievement of therapeutic benefits while mitigating harmful effects.
Solution Approach 2:
The patent changes the chemical composition parameters by replacing synthetic estradiol with a combination of plant-derived compounds (genistein from soy and curcumin from turmeric). This parameter change maintains estrogenic benefits while reducing carcinogenic risks associated with conventional HRT.
2Object-affected harmful factors
If selective estrogen receptor modulators (SERMs) like tamoxifen are used to reduce breast cancer risk, then breast cancer incidence is reduced, but hot flushes and uterine cancer risk increase
Solution Approach 1:
The patent introduces curcumin as an intermediary substance that modulates the action of genistein. Curcumin enhances the anti-estrogenic effects in breast tissue while attenuating the hot flushes and uterine cancer risks associated with SERMs. This intermediary approach allows selective estrogen modulation without the adverse effects of conventional SERMs.
Solution Approach 2:
The patent changes the pharmacological parameters by using plant-derived compounds with different binding affinities and tissue selectivity compared to synthetic SERMs. The combination of genistein and curcumin provides selective estrogenic/anti-estrogenic effects with a more favorable side effect profile.
3Reliability
If conventional HRT is used to treat osteoporosis and climacteric symptoms, then bone density and symptom relief are improved, but mammary and uterine hyperplasia occur
Solution Approach 1:
The patent segments the estrogenic response by using two plant extracts with complementary actions: genistein provides tissue-selective estrogenic effects for bone and cardiovascular protection, while curcumin provides anti-proliferative effects to prevent hyperplasia in mammary and uterine tissues.
Solution Approach 2:
The patent creates a composite therapeutic approach by combining two plant-derived compounds (genistein and curcumin) that work synergistically. This composite formulation achieves bone protection and symptom relief while preventing hyperplastic effects through the anti-estrogenic and anti-proliferative properties of curcumin.
Data Source
AI summary
Extracts of various species of the Moraceae family have estrogenic properties. For example, aqueous and ethanolic extracts of Scutellaria barbata D. Don of the Labiatae Family species possess estrogenic properties in both ERα+ and ERβ+ cells. These estrogenic effects include estrogen response element (ERE) stimulation as well as tumor necrosis factor (TNF) repression. Methods are provided for treating climacteric symptoms, breast and/or uterine cancer, and osteoporosis.